Literature DB >> 6282764

Enzymes of collagen synthesis and type III procollagen amino-propeptide in serum from Nigerians with hepato-cellular carcinoma and other malignant diseases.

D M Bolarin, E R Savolainen, K I Kivirikko.   

Abstract

Serum immunoreactive prolyl hydroxylase protein (S-IRPH), galactosylhydroxylysyl glucosyltransferase activity (S-GGT) and the amino-terminal propeptide of type III procollagen [S-Pro(III)-N-P] were studied in 24 patients with primary hepatocellular carcinoma, 18 with secondary liver neoplasms and 35 with other malignant diseases but no evidence of liver involvement; this latter group included 13 patients with Burkitt's lymphoma, 11 with breast cancer and 11 with other neoplasms. Control values were determined for 60 apparently healthy Nigerians, S-IRPH and S-GGT were above the upper normal limit, defined as the mean + 2 SD of the controls, in all the patients with primary hepatocellular carcinoma and all but one with secondary liver neoplasms, whereas only one S-IRPH value and three S-GGT values exceeded this limit in the patients with other malignant diseases. The mean S-Pro(III)-N-P was even more elevated than S-IRPH and S-GGT in the primary and secondary liver neoplasm cases, but was also elevated in other malignant neoplasms; about one third of the patients with no evidence of liver involvement had a concentration exceeding the upper normal limit. A high correlation was found between the values for the three assays both in primary hepatocellular carcinoma and in the whole series of malignant diseases. The data suggest that primary and secondary malignant neoplasms of the liver have a high rate of collagen synthesis. The three assays may be of some value in the diagnosis of primary hepatocellular carcinoma and secondary liver involvement in other malignant diseases, and in monitoring the treatment provided.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6282764     DOI: 10.1002/ijc.2910290407

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Diagnostic value of measurement of serum type I procollagen carboxy terminal peptides in patients with scirrhous carcinoma of the stomach.

Authors:  K Kohda; N Ito; M Ohwada; K Morita; N Watanabe; Y Kohgo; Y Mogi; Y Niitsu
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

2.  Serum enzymes of collagen synthesis and type III procollagen aminopropeptide in Nigerian patients with sickle cell disease.

Authors:  D M Bolarin
Journal:  J Natl Med Assoc       Date:  1986-07       Impact factor: 1.798

3.  Prolonged exercise causes an increase in the activity of galactosylhydroxylysyl glucosyltransferase and in the concentration of type III procollagen aminopropeptide in human serum.

Authors:  T E Takala; J Vuori; H Anttinen; K Väänänen; R Myllylä
Journal:  Pflugers Arch       Date:  1986-11       Impact factor: 3.657

4.  Enzymes of collagen synthesis and type III procollagen aminopropeptide in the evaluation of D-penicillamine and medroxyprogesterone treatments of primary biliary cirrhosis.

Authors:  E R Savolainen; T A Miettinen; P Pikkarainen; M P Salaspuro; K I Kivirikko
Journal:  Gut       Date:  1983-02       Impact factor: 23.059

5.  Procollagen type III N-peptide and type IV collagen 7S-domain in the sera of breast cancer patients.

Authors:  T Narita; H Funahashi; Y Satoh; H Takagi
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

6.  Human prolyl hydroxylase. Purification, radioimmunoassay and clinical studies in liver diseases.

Authors:  Y Nagai; H Oka
Journal:  Gastroenterol Jpn       Date:  1985-02

7.  Clinical studies of type-I procollagen carboxyterminal peptide in serum of patients with gastric cancer: comparison with CEA and CA19-9.

Authors:  K Ogawa; Y Naritaka; T Katsube; Y Ohtani; H Yagawa; T Kajiwara
Journal:  J Gastroenterol       Date:  1994-06       Impact factor: 7.527

8.  Type III collagen metabolism in soft tissue sarcomas.

Authors:  T A Wiklund; I Elomaa; C P Blomqvist; L Risteli; J Risteli
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.